Previous 10 | Next 10 |
During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer ( PFE ) has a huge windfall from its Covid-19 vaccine. Pfizer is now under pressure to limit that windfall and spend it on new treatments. The company also faces a patent cliff on its other drugs. Sou...
Biotechnology exchange traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) hovers near its one-year trading low, but the investment community has shown recent interest in the fund as the ETF has experienced a large influx of capital in 2022. While XBI trades down 27% on the yea...
The private sector balance increased by over $293+ billion in March 2022. Credit creation from commercial banks was strong at $174B+. The seasonal pattern is down until early-to-mid May as the market negotiates a series of liquidity sinkholes from federal tax collection. Fed r...
Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...
Since the beginning of COVID-19, companies and countries have struggled to ensure steady supply of key inputs to the normal functioning of our economies. Synthetic biology is a revolutionary technology that could make a profound impact on the way a vast array of products are manufactu...
Typically, we look at net new highs as a way to confirm moves in the broader market. At the high last Wednesday, over 90% of S&P 500’s new highs came from defensive sectors. In other words, defensives have been a notable pocket of strength recently. For further de...
Stock markets fell in the first quarter as Russia’s invasion of Ukraine destabilized the growth outlook, amplified concerns about rising interest rates and unleashed geopolitical risks. While the conflict has created many uncertainties, we believe the impact of persistent infla...
We are initiating ACHV with a buy rating and a target price of USD 70. The company is developing a smoking cessation treatment, cytisinicline, with an estimated USD 200-300M peak sales (risk-adjusted). Cytisinicline has completed a phase 3 study, and the top-line data will be rele...
On March 26th, Provention Bio announced that the FDA accepted the BLA submission of Teplizumab for the delay of type 1 diabetes (T1D) indication for at-risk individuals. The goal date for PDUFA is August 17th. Until then, there is no meaningful catalyst, meaning the stock could trade ...
News, Short Squeeze, Breakout and More Instantly...
iShares Biotechnology ETF Company Name:
IBB Stock Symbol:
NASDAQ Market:
2024-07-19 00:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 22:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...